¹Ì±¹ÀÇ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Á¦Ç°¡¤¼­ºñ½ºº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹® ¿¹Ãø(2024-2030³â)
U.S. Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Oligonucleotides, Equipment/Synthesizer), By Application (PCR Primers, Sequencing), By End-use, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1493385
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 90 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,191,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,568,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,321,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì±¹ÀÇ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ½ÃÀå ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¹Ì±¹ÀÇ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 30¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2030³âÀÇ CAGRÀº 12.80%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ºÐÀÚÁø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, »õ·Î¿î ¿ëµµÀÇ ÃâÇö, ½ÉÇ÷°ü Áúȯ, ¸Á¸· Áúȯ, ¾Ï°ú °°Àº ³­Ä¡¼º ÀûÀÀÁõ¿¡ ´ëÇÑ »õ·Î¿î °¡´É¼ºÀ¸·Î ÀÎÇÑ ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¿¹Ãø ±â°£ Áß ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº ¹Ì±¹ÀÇ ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼º »ê¾÷¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª Àü¿°º´ ±â°£ Áß ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼º¿¡ ´ëÇÑ ¼ö¿ä´Â Á¦¾àȸ»ç¿Í ÀÇ·á Àü¹®°¡µéÀÌ ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵åÀÇ º¸´Ù È¿À²ÀûÀÎ »ç¿ë¹ýÀ» ã¾Æ³»°í COVID-19ÀÇ È®»êÀ» ¾ïÁ¦Çϱâ À§ÇØ ±× ÀÀ¿ë¿¡ ÃÊÁ¡À» ¸ÂÃ߸鼭 ¼ºÀåÇß½À´Ï´Ù. ¿¹¸¦ µé¾î Innovative Genomic Institute´Â 2020³â¿¡ COVID-19 °¨¿°À» Ä¡·áÇϱâ À§ÇØ È£Èí ¶Ç´Â ºÐ¹«±â·Î ÈíÀÔÇÒ ¼ö ÀÖ´Â ¿¡¾î·ÎÁ¹È­µÈ Àá±Ý ÇÙ»ê º¯Çü ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¸¦ °³¹ß ÁßÀ̶ó°í ¹àÇû½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ °ü½ÉÀ» ºÒ·¯ ÀÏÀ¸Ä×½À´Ï´Ù. µû¶ó¼­ Àü¿°º´Àº ¹Ì±¹ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.

¶ÇÇÑ ±â¾÷Àº ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ±â¹Ý Ä¡·áÁ¦¸¦ °³¹ßÇϱâ À§ÇØ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 10¿ù GSK plc¿Í Arrowhead Pharmaceuticals´Â Á¸½¼¾ØµåÁ¸½¼ »êÇÏ Janssen Pharmaceuticals, Inc. GSK¿¡ JNJ-9989ÀÇ °³¹ß ¹× »ó¾÷È­ µ¶Á¡±ÇÀ» ¾çµµÇÏ´Â °è¾àÀ» ü°áÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¾á¼¾Àº 2018³â ¾Ö·Î¿ìÇìµå·ÎºÎÅÍ JNJ-3989(ÀÌÀü¿¡´Â ARO-HBV)¸¦ µµÀÔÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦¾à»çµéÀÇ À¯»çÇÑ ³ë·ÂÀº ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼ºÀº ³ôÀº ÀáÀç·ÂÀ» °¡Áø ¿ëµµÀÌÁö¸¸, ½Ç¿ëÈ­¿¡´Â ¿©·¯ °¡Áö ¹®Á¦°¡ ÀÖ½À´Ï´Ù. ÇÕ¼º¿¡¼­ ³ôÀº ¼öÀ²À» ¾ò±â À§ÇØ °¡Àå Áß¿äÇÑ ¸Å°³º¯¼ö Áß Çϳª´Â °áÇÕ È¿À²À» ¸ð´ÏÅ͸µÇÏ´Â °ÍÀÔ´Ï´Ù. Æò±Õ Ä¿Çà ¸µÀÇ ÀÛÀº ½ÇÆÐÀ²µµ ±ä ½ÃÄö½Ì¿¡¼­ ±ØÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. Æò±Õ Ä¿Çà ¸µ ½ÇÆÐÀ²ÀÇ ÀÛÀº º¯È­´Â ½ÇÁúÀûÀÎ ¼ø È¿°ú·Î À̾îÁý´Ï´Ù. µû¶ó¼­ °¢ ¸ÂÃãÇü ÇÕ¼ºÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µÀº °¢ Ç÷§Æû¿¡ ÇʼöÀûÀÌ¸ç ½ÃÀå ¼ºÀåÀ» ¾î´À Á¤µµ ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼º ½ÃÀå º¸°í¼­ - ÁÖ¿ä ³»¿ë

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¹Ì±¹ÀÇ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ½ÃÀå : Á¦Ç°°ú ¼­ºñ½º ºñÁî´Ï½º ºÐ¼®

Á¦5Àå ¹Ì±¹ÀÇ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ½ÃÀå : ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦6Àå ¹Ì±¹ÀÇ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ½ÃÀå : ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦7Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

U.S. Oligonucleotide Synthesis Market Growth & Trends:

The U.S. oligonucleotide synthesis market size is anticipated to reach USD 3.09 billion by 2030 and is projected to grow at a CAGR of 12.80% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising demand for molecular diagnostics, emerging novel applications, and growing demand for oligonucleotide therapeutics owing to the emerging potential for incurable indications such as cardiovascular diseases, retinal disorders, and cancer are anticipated to increase the demand for oligonucleotide synthesis over the forecast period.

The COVID-19 pandemic has had a positive impact on the U.S. oligonucleotide synthesis industry. During the pandemic, however, the demand for oligonucleotide synthesis grew as pharmaceutical companies and healthcare professionals focused on identifying more efficient usage of oligonucleotides and their application to limit the spread of COVID-19. For instance, the Innovative Genomic Institute stated in 2020 that it was developing an aerosolized, locked nucleic acid modifying antisense oligonucleotide that can be breathed or nebulized to treat COVID-19 infection. Such advances piqued the interest of healthcare providers. Hence, the pandemic has had a favorable impact on the U.S. market.

Moreover, companies have increased investments to develop oligonucleotide-based therapeutics. For instance, in October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK the exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.

However, oligonucleotide synthesis encounters challenges and problems in practical applications, even with high-potential applications. One of the most critical parameters to get a high yield from synthesis is monitoring its coupling efficiency. Even the slightest rate of failure in average coupling causes dramatic effects in long sequences. A minor change in average coupling failure leads to a substantial net effect. Thus, real-time monitoring of each custom synthesis becomes essential for every platform and, thereby, is anticipated to hamper the growth of the market to a certain extent.

U.S. Oligonucleotide Synthesis Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. U.S. Oligonucleotide Synthesis Market: Product & Service Business Analysis

Chapter 5. U.S. Oligonucleotide Synthesis Market: Application Business Analysis

Chapter 6. U.S. Oligonucleotide Synthesis Market: End-use Business Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â